Research Focus

Medicine; Chief, Assoc Attend

Recent additions – View all

1. Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer

   Journal Article

   Forde, P. M.; Spicer, J. D.; Provencio, M.; Mitsudomi, T.; Awad, M. M.; Wang, C.; Lu, S.; Felip, E.; Swanson, S. J.; Brahmer, J. R.; more...
   New England Journal of Medicine (2025)

   Fulltext@MSK | Save
2. Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816

   Meeting Abstract

   Forde, P. M.; Spicer, J.; Provencio, M.; Mitsudomi, T.; Awad, M. M.; Wang, C.; Lu, S.; Felip, E.; Broderick, S.; Swanson, S.; more...
   Journal of Clinical Oncology (2025)

   Fulltext@MSK | Save
3. Perioperative nivolumab (NIVO) vs placebo (PBO) in patients (pts) with resectable NSCLC: Updated survival and biomarker analyses from CheckMate 77T

   Meeting Abstract

   Cascone, T.; Awad, M. M.; Spicer, J.; He, J.; Lu, S.; Tanaka, F.; Cornelissen, R.; Petruzelka, L. B.; Ito, H.; De Oliveira Koch, L.; more...
   Journal of Clinical Oncology (2025)

   Fulltext@MSK | Save